Risperdal is an atypical antipsychotic drug that is approved for treating acute and maintenance schizophrenia in adults, schizophrenia in adolescents aged 13-17 years, bipolar mania monotherapy for both adults and pediatrics, short-term treatment of acute manic or mixed episodes of Bipolar I Disorder in adults and children and adolescents aged 10-17 years, and irritability associated with autism disorder in children and adolescents aged 5-16 years. Risperdal has been linked to diabetes; prompting the FDA to request that Risperdal manufacturers, Janssen and Johnson & Johnson, issue a warning to patients and prospective patients. In a recent study, Risperdal increased a patient's chances of developing diabetes by about 50 percent compared with older antipsychotics.  Risperdal has also been linked to increased mortality in elderly patients with dementia-related psychosis, cerebrovascular adverse events, including strokes, in elderly patients with related psychosis, Neuroleptic Malignant Syndrome (NMS), Tardive Dyskinesia, and hyperprolactinemia. Risperdal has been known to cause seizures, irregular heartbeats, muscle weakness and spasms, high fever, constipation, weight gain and headaches